#4 - Pfizer (NYSE:PFE)
Pfizer Inc. (NYSE: PFE) is a multibillion-dollar biopharmaceutical company that generated over $63 billion in revenue in 2024. While that was down from the $81 billion that it generated in 2021, which was largely from its COVID-19 vaccine and therapeutics. However, the company has 10 drugs that each add at least $1 billion to its top line.
Investors know that to succeed in the biopharmaceutical sector, you need to look to the future. Pfizer has an extensive pipeline with 115 candidates, including 32 drugs in Phase 3 trials. Many of those candidates are in oncology.
Investors may have to wait for that growth. However, PFE stock offers a dividend that may make it worth the wait. The stock’s dividend yield is 6.67%, and the company has increased it for 16 consecutive years.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
More about Pfizer- Current Price
- $23.11
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 6 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $29.17 (26.2% Upside)
